CGTX Company Profile and Key Details

Short-term trend indicators are mixed aligned (SMA20 6.23%, SMA50 -10.63%, SMA200 -6.68%). The stock’s 14-day RSI is 49.35 (neutral), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -69.71% below its high and over 421.81% above its low. Average 10-day trading volume of 611.52 thousand shares is below the 3-month average of 888.70 thousand, indicating normal recent market interest.

Cognition Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.61. This means the shares are trading above this model’s fair value.

Cognition Therapeutics, Inc. generated EPS of -$0.47 over the past year. Five-year average earnings growth is -16.44%. Wall Street analysts project EPS growth of 20.63% annually over the next five years. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.08. Next year's EPS is expected at -$18.06. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 7 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $3.00. The high target offers 654.72% upside. The low target suggests 183.02% downside. The mean target is $4.14. This offers 290.57% upside. Cognition Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 06, 2025, missed forecasts by -14.29%. The prior quarter beat by -8.33%. Over the last six quarters, Apple has recorded several small beats. These include -99.92% in August 08, 2024.

Cognition Therapeutics, Inc. (NASDAQ:CGTX) closed at $1.06 USD, losing -$0.03 (-2.75%) from the previous close of $1.09. The stock is currently mid-range between its 52-week high and low $0.22 and $3.83. With a market capitalization of about $78.00 million, Cognition Therapeutics, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.25). Key stats such as the average daily volume over the past year has been around 904.56 thousand shares, in line with its 52-week average. Headquartered in Purchase, NY, Cognition Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Lisa Ricciardi, the company employs approximately 25 people and listed since October 08, 2021. Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Cognition Therapeutics, Inc. has 88.27 million shares outstanding. The public float is 81.77 million shares, elevated short interest at 8.95% of float. This equals 7.34 million shares. The short ratio is 6.05 days. Institutional investors hold 12.83% of the float. Insiders own 0.7%. Ogden CAP Associates, LLC holds 2.21 million shares, Golden Seeds Cognition Therapeutics LLC has 2.18 million shares and Breedlove Mark H. has 404.44 thousand shares.

Cognition Therapeutics, Inc. trades at a P/E ratio of -2.97, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 2.27 suggesting the stock is closer to book value. The P/FCF stands at -2.65, also above market averages.

Our AI price prediction model suggests that Cognition Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.77%, with price expected at $1.02 by March 13, 2026, within a range of $0.93 to $1.11 3-Month Outlook: Projected fall of -79.25%, reaching $0.22 by May 28, 2026, with a range of $0.13 to $0.26. 1-Year Outlook: Projected gain of 658.49%, with price at $8.04 by February 26, 2027, within a range of $7.93 to $8.16.

Cognition Therapeutics, Inc. (NASDAQ:CGTX) shares are flat 3.7% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Cognition Therapeutics, Inc. trading at a premium to the broader market with a P/E of -2.97. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.88, suggesting 643.4% upside. Our AI forecast model points to short-term weakness (-3.77% over two weeks), a medium-term fall (-79.25% over three months), and a longer-term gain (658.49% over one year), with expected trading ranges indicating moderate volatility.